A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

New findings reveal promising efficacy of irpagratinib and atezolizumab in treating advanced hepatocellular carcinoma with ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Zev A. Wainberg, MD, discussed the significance of the immune response signals in a phase 1 trial of an amphiphile vaccine for pancreatic cancer.

Jason Luke, MD, FACP, discusses the mechanism of action of IMA203, a novel agent for the treatment of metastatic melanoma.

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, ...

Atezolizumab and bevacizumab enhance TACE effectiveness, significantly extending progression-free survival in unresectable ...

A promising allogeneic CAR-T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments ...

New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, ...